Halozyme Therapeutics — Jan 28, 2026 release

2026 Financial Guidance Previous Guidance Range New Guidance Range Expected YoY Growth 2 Total Revenue $1,430 to $1,530 million $1,710 to $1,810 million 23% to 30% Royalty Revenue $900 to $940 million $1,130 to $1,170 million 30% to 35% Adjusted EBITDA $1,000 to $1,080 million $1,125 to $1,205 million ------ Non-GAAP Diluted EPS $6.50 to $7.00 $7.75 to $8.25 ------ Footnotes: 1 Growth rates calculated from 2024 actual to low end of 2025 range and high-end of 2025 range. 2 Growth rates calculated from 2025 midpoint to low end of 2026 range and high-end of 2026 range. 3 Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. 4 Including investment of approximately $60 million for Hypercon™ and Surf Bio not included in prior 2026 guidance. Webcast and Conference Call Halozyme will host an Investor Conference Call today, Wednesday, January 28 at 5:30am PT/8:30am ET. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969 . A webcast of the live call and presentation materials will be available through the "Investors" section of Halozyme's corporate website at ir.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated